Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Non-Severe Community-Acquired Pneumonia.

Article Details

Citation
Copy to clipboard

Tannous A, Levinson SL, Bolognese J, Opal SM, DiNubile MJ

Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Non-Severe Community-Acquired Pneumonia.

Antimicrob Agents Chemother. 2020 Jul 20. pii: AAC.00579-20. doi: 10.1128/AAC.00579-20.

PubMed ID
32690640 [ View in PubMed
]
Abstract

Background. There remains an unmet need to address the substantial morbidity and mortality associated with severe community-acquired pneumonia (sCAP). Recombinant human plasma gelsolin (rhu-pGSN) improves disease outcomes in diverse animal models of infectious and non-infectious inflammation.Methods. This blinded dose-escalation safety study involved non-ICU patients admitted for mild CAP and randomized 3:1 to receive adjunctive rhu-pGSN or placebo intravenously. Thirty-three subjects were treated: 8 in the single-dose phase and 25 in the multi-dose phase. For the single-dose phase, rhu-pGSN 6 mg/kg was administered once. For the multi-dose phase, a daily rhu-pGSN dose of 6, 12, or 24 mg/kg was given on 3 consecutive days.Results Adverse events (AEs) were generally mild in both treatment groups irrespective of dose. The only serious (S)AE in the single-dose phase was a non-drug related pneumonia in a rhu-pGSN recipient who died after institution of comfort care. One single-dose placebo recipient had a drug-related AE (maculo-papular rash). In the multi-dose phase, there were 2 SAEs in 1 placebo recipient, including a fatal pulmonary embolism. In the 18 rhu-pGSN recipients in the multi-dose phase, there were no serious or drug-related AEs, and nausea and increased blood pressure were each reported in 2 patients. The median rhu-pGSN half-life exceeded 17 hours with all dosing regimens, and supraphysiologic levels were maintained throughout the 24-hour dosing interval in the 2 highest dosing arms.Conclusions Rhu-pGSN was well tolerated overall in CAP patients admitted to non-ICU beds, justifying a larger proof-of-concept trial in an ICU population admitted with sCAP.

DrugBank Data that Cites this Article

Drugs